From Cell Line to Market: Accelerating Biologics Development
Using GPEx® Lightning as a case study, the session will explore how cell line development approaches can improve stability, speed, and scalability in mAbs and next-generation multispecifics / complex biologics. This platform illustrates how high-titer expression and stable integration across diverse protein modalities can accelerate candidate selection, development, and manufacturing.
Three Takeaways
- Speed: only 25 days to stable pools, suitable for generation of non-GMP material
- High titer expression across modalities: 15+g/L for mabs, 11+g/L for bsAbs, 3+g/L for recombinant proteins
- Stable and Scalable: 60+ generations of stability and proven consistency from Ambr250® to GMP bioreactors
Agenda
11:45 Welcoming and lunch
12:00 Knowledge sharing presentation and Q&A
13:00 Mingling with coffee
Speaker
Emily Schirmer, General Manager, Catalent Madison
About Catalent
Catalent about themselves: Catalent Biologics offers protein biologics development and manufacturing from cell line through to commercial supply. Our state-of-the-art facilities offering right scale flexible clinical and commercial manufacturing, integrated process development and analytical services to solve your most difficult development and biomanufacturing challenges. At Catalent, we champion the missions that matter to help people live better and healthier lives.